Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Feb;28(1):e111-e117.
doi: 10.1097/MJT.0000000000000906.

Drug Repositioning in Oncology

Marissa B Serafin  1 , Angelita Bottega  1 , Taciéli F da Rosa  1 , Catrine S Machado  1 , Vitória S Foletto  2 , Silvana S Coelho  1 , Augusto D da Mota  2 , Rosmari Hörner  1   2
Affiliations

Drug Repositioning in Oncology

Marissa B Serafin et al. Am J Ther. 2021 Jan-Feb.

Abstract

Background: The worldwide increase in the occurrence of cancer associated with the limitations of immunotherapy and the emergence of resistance have impaired the prognosis of cancer patients, which leads to the search for alternative treatment methods. Drug repositioning, a well-established process approved by regulatory agencies, is considered an alternative strategy for the fast identification of drugs, because it is relatively less costly and represents lower risks for patients.

Areas of uncertainty: We report the most relevant studies about drug repositioning in oncology, emphasizing that its implementation faces financial and regulatory obstacles, making the creation of incentives necessary to stimulate the involvement of the pharmaceutical industry.

Data sources: We present 63 studies in which 52 non-anticancer drugs with anticancer activity against a number of malignancies are described.

Therapeutic innovations: Some have already been the target of phase III studies, such as the Add-Aspirin trial for nonmetastatic solid tumors, as well as 9 other drugs (aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, and sertraline) in the CUSP9* clinical trial for the treatment of recurrent glioblastoma. Others have already been successful in repositioning such as thalidomide, zoledronic acid, celecoxib, methotrexate, and gemcitabine.

Conclusions: Therefore, drug repositioning represents a promising alternative for the treatment of oncological disorders; however, the support from funding agencies and from the government is still needed, the latter regarding regulatory issues.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Accessed July 20, 2018.
    1. The Lancet Oncology. Calling time on the immunotherapy gold rush. Lancet Oncol. 2017;18:981.
    1. Markman M. Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131:241–245.
    1. Wiggins HL, Wymant JM, Solfa F, et al. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem Pharmacol. 2015;93:332–342.
    1. Kim M, Choe MH, Yoon YA, et al. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells. Biochem Pharmacol. 2017;144:78–89.

LinkOut - more resources